4.2 Essential Documents Checklist (ICH E6 Section 8)

4.2 Essential Documents Checklist (ICH E6 Section 8)

Overview of Essential Documents

Under ICH E6 Section 8, essential documents are defined as those documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor, and monitor with the standards of Good Clinical Practice (GCP) and with all applicable regulatory requirements. They are typically filed in the Investigator Site File (ISF) at the clinical site and the Trial Master File (TMF) at the sponsor's office. During inspections by regulatory authorities (like the FDA), these files are heavily scrutinized to reconstruct the trial and verify data integrity.

Categorization by Trial Phase

ICH E6 Section 8 categorizes essential documents into three distinct chronological phases of the clinical trial:

1. Before the Clinical Phase of the Trial: These documents demonstrate that the site, investigator, and sponsor are fully prepared, qualified, and authorized to start the trial. They establish that the protocol has been approved, safety disclosures have been collected, and facilities are ready.
2. During the Conduct of the Trial: These documents provide a continuous record of the trial's execution. They verify that protocol amendments are approved, safety events are reported, subject safety is monitored, and the investigational product is accounted for.
3. After Completion or Termination of the Trial: These documents confirm that all study procedures have been completed, all data has been captured, all IP has been accounted for, and all regulatory notifications have been sent.

---

Core Regulatory Documents and Commitments

Form FDA 1572: Statement of Investigator

For clinical trials conducted under an Investigational New Drug (IND) application, the Form FDA 1572 is a legally binding contract between the Principal Investigator (PI) and the United States Food and Drug Administration (FDA). By signing the 1572, the investigator commits to specific regulatory responsibilities.

The Form FDA 1572 contains critical site-specific information, including the PI's name and address, the addresses of all clinical trial sites, the addresses of any clinical laboratories used, the name and address of the reviewing IRB, and a list of all sub-investigators (co-investigators, research fellows, or coordinators making significant clinical contributions).

When signing the 1572, the investigator formally pledges to:

1. Conduct the study in accordance with the current protocol and make changes only after sponsor agreement, except to protect subject safety.
2. Personally supervise or conduct the study.
3. Ensure that all associates, colleagues, and employees assisting in the study are informed of their obligations.
4. Obtain informed consent in accordance with 21 CFR Part 50 and ensure IRB review/approval in accordance with 21 CFR Part 56.
5. Report to the sponsor any adverse experiences in accordance with 21 CFR 312.64.
6. Read and understand the Investigator’s Brochure.
7. Maintain adequate and accurate records (including case histories) in accordance with 21 CFR 312.62 and make them available for inspection.
8. Submit initial and ongoing reviews to the IRB, and report all prompt changes or unanticipated problems.
9. Comply with all other requirements of 21 CFR Part 312.

Exam Trap: A common misconception is that the Form FDA 1572 is submitted directly to the FDA by the site. In reality, the site submits the signed Form FDA 1572 to the sponsor, who then submits it to the FDA as part of the IND application.

Financial Disclosures (21 CFR Part 54)

Under 21 CFR Part 54, clinical investigators must disclose any financial interests that could potentially bias the outcome of the clinical trial. This regulation applies to the PI and all sub-investigators listed on the Form FDA 1572. The sponsor is required to collect these disclosures before permitting an investigator to participate.

The specific financial disclosure thresholds that must be reported are:

• Significant Payments of Other Sorts (SPOOS): Any payments from the sponsor to the investigator or their institution that exceed $25,000 (excluding the cost of conducting the clinical trial) during the study and for one year following its completion.
• Proprietary Interest: Any proprietary interest in the tested product, such as a patent, trademark, copyright, or licensing agreement.
• Equity Interest in a Publicly Held Sponsor: Any stock, stock options, or equity interest that exceeds $50,000 during the trial and for one year post-trial.
• Equity Interest in a Non-Publicly Held Sponsor: Any equity interest (no matter the dollar value) in a privately held sponsor.

These disclosures must be collected at the start of the study, updated if any financial status changes during the trial, and monitored for one year after the study's completion.

Delegation of Authority (DOA) Log

While the PI remains ultimately responsible for the conduct of the trial, they can delegate specific tasks to qualified study staff. The Delegation of Authority (DOA) Log (or Delegation of Tasks Log) documents this delegation. It must list:

• The name and signature of the study staff member.
• The specific delegated tasks (e.g., obtaining informed consent, performing physical exams, dispensing IP, entering CRF data).
• The start date of delegation and, if applicable, the end date.
• The PI's signature and date approving each delegation.

Staff members must not perform any study tasks prior to being officially delegated and trained. Back-dating a delegation log is a severe GCP violation.

Curriculum Vitae (CVs), Licenses, and Lab Documentation

To prove investigator and facility qualifications, the site must maintain current Curriculum Vitae (CVs) and active medical/professional licenses for all investigators and sub-investigators (usually updated every 2-3 years).

For clinical laboratories, the site must maintain:

• Lab Certifications: Proof of accreditation, such as CLIA (Clinical Laboratory Improvement Amendments) or CAP (College of American Pathologists) certificates.
• Normal Ranges: Current laboratory reference ranges (normal values) for all tests specified in the protocol. If the laboratory updates its reference ranges during the study, the site must obtain the new range sheet immediately, document the date it takes effect, and archive the old ranges.